We thank the reviewer for this comment, as these additions add much clarity to the mechanism of action of TTFields in combination with sorafenib and provide a more coherent explanation for the in vivo results.
Can this dose observed in vitro on only tumor cells be translated to in vivo work where the tumor microenvironment is totally different?